Special Issue

EBV and Autoimmune Disease

Message from the Guest Editor

Epstein-Barr Virus (EBV), the first human tumor virus. EBV reactivation from latency induces host cells to differentiate into plasma cells as the virus starts expressing proteins of the lytic cycle to produce infectious progeny. Whilst much of what is known about EBV comes from its association with cancer, emerging evidence suggests that the virus may also play a critical role in pathogenesis of several autoimmune diseases, thus adding another complexity to the mosaic of autoimmunity. The large diffusion of this virus (95% people worldwide are infected) and the fact that EBV lodges in B lymphocytes, fundamental for adaptive humoral immunity, suggest a delicate balance between the virus and immune responses. Decades of research into how EBV escapes immune eradication has provided important information regarding the virus-host interaction, but the new challenge today is to clarify how EBV controls and triggers immune response and, as a consequence, sometimes leads to aberrant autoimmune reactions.

Guest Editor

Dr. Antonella Farina

Institute Pasteur-Fondazione Cenci Bolognetti, Department of Experimental Medicine, "Sapienza", University of Rome, Rome, Italy

Deadline for manuscript submissions

closed (30 September 2021)



Microorganisms

an Open Access Journal by MDPI

Impact Factor 4.2 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/76820

Microorganisms
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
microorganisms@mdpi.com

mdpi.com/journal/microorganisms





Microorganisms

an Open Access Journal by MDPI

Impact Factor 4.2 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

"Microorganism" merges the idea of the very small with the idea of the evolving reproducing organism is a unifying principle for the discipline of microbiology. Our journal recognizes the broadly diverse yet connected nature of microorganisms and provides an advanced publishing forum for original articles from scientists involved in high-quality basic and applied research on any prokaryotic or eukaryotic microorganism, and for research on the ecology, genomics and evolution of microbial communities as well as that exploring cultured microorganisms in the laboratory.

Editor-in-Chief

Dr. Nico Jehmlich

Department of Molecular Toxicology, UFZ-Helmholtz Centre for Environmental Research, 04318 Leipzig, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, PubAg, CAPlus / SciFinder, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Microbiology) / CiteScore - Q1 (Microbiology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.2 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).

